Niraparib, Free Base

Niraparib, Free Base
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
LC-N-5665_5mg 5 mg -

3 - 15 Werktage*

75,00 €
LC-N-5665_10mg 10 mg -

3 - 15 Werktage*

90,00 €
LC-N-5665_25mg 25 mg -

3 - 15 Werktage*

110,00 €
LC-N-5665_50mg 50 mg -

3 - 15 Werktage*

132,00 €
LC-N-5665_100mg 100 mg -

3 - 15 Werktage*

181,00 €
LC-N-5665_200mg 200 mg -

3 - 15 Werktage*

286,00 €
LC-N-5665_500mg 500 mg -

3 - 15 Werktage*

533,00 €
LC-N-5665_1g 1 g -

3 - 15 Werktage*

762,00 €
LC-N-5665_2g 2 g -

3 - 15 Werktage*

1.220,00 €
 
Soluble in DMSO. Niraparib, also known as MK-4827, is a poly(ADP-ribose)polymerase (PARP)... mehr
Produktinformationen "Niraparib, Free Base"
Soluble in DMSO. Niraparib, also known as MK-4827, is a poly(ADP-ribose)polymerase (PARP) inhibitor. Niraparib displayed excellent PARP 1 and 2 inhibition with IC50 values of 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibited PARP activity with an IC50 of 4 nM, and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2, with IC50 values of 10-100 nM. Niraparib was well tolerated in vivo and showed antitumor activity as a single agent in a xenograft model of BRCA-1 deficient cancer. Jones P., et al. 'Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.' J. Med. Chem. 52: 7170-7185 (2009). Niraparib enhanced radiation-induced cytotoxicity in neuroblastoma cells. In vivo treatment with niraparib and radiation prolonged survival of mice in a murine xenograft model of metastatic neuroblastoma when compared to single modalities. Mueller S., et al. 'Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma.' Anticancer Res. 33: 755-762 (2013). A phase 1 clinical trial demonstrated niraparib inhibited PARP more than 50% at doses greater than 80 mg/day and had antitumour activity at doses beyond 60 mg/day. Antitumour activity of niraparib was reported in BRCA1 or BRCA2 mutation carriers with ovarian cancer, breast cancer, and in patients with sporadic high-grade serous ovarian cancer, non-small-cell lung cancer, and prostate cancer. Sandhu S.K., et al. 'The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.' Lancet Oncol. 14: 882-892 (2013).
Schlagworte: MK-4827
Hersteller: LC Laboratories
Hersteller-Nr: N-5665

Eigenschaften

Anwendung: Antineoplastic, PARP inhibitor
MW: 320.39 D
Formel: C19H20N4O
Reinheit: >99%
Format: Solid

Datenbank Information

CAS : 1038915-60-4| Finde Alternativen
KEGG ID : K10798 | Finde Alternativen

Handhabung & Sicherheit

Lagerung: -20°C
Versand: +20°C (International: +20°C)
Signalwort: Warning
GHS-Piktogramme:
H-Sätze: H302+H312+H332
P-Sätze: P262
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier folgen Informationen zur Produktreferenz. mehr
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Niraparib, Free Base"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen